Drug Ridlor 75mg MSN prevents blood coagulation complications (3 blisters x 10 tablets)

Nervous system disorders:

When experiencing side effects of the drug, patients need to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Caution when using

bleeding and hematurian disorders

Due to the risk of bleeding and adverse interactions about hematology, it should quickly consider the identification of blood cells and other appropriate tests when clinical symptoms show that bleeding appears during treatment.

As other anti-platelet aggregation, should be cautious when using clopidogel in patients at risk of increased bleeding due to injury, anatomy or other pathological conditions and in patients who are being treated with ASA, heparin, Glycoprotein IFB/LLA inhibitors or Non-Stoid anti-inflammatory (NSAIDs), including COX-2 inhibitors.

Patients should carefully monitor any signs of bleeding, including bleeding, especially during the first week of treatment and/or after the intervention or anatomical process.

It is not recommended that the use of clopidogel and oral anticoagulants because of increasing bleeding level. If the patient is about to undergo selective surgery and the temporary dynamic effect is not necessary, Clopidogel should be stopped 7 days before surgery.

Patients should notify the doctor or dentist whether they are taking clopidogel before surgery and before using any new medicine. Clopidogel prolongs the bleeding time and should be used carefully in patients with traces that often have bleeding (especially digestion and intraocularity).

Tell patients when using clopidogel (individually or in combination with ASA), maybe the bleeding time is longer than usual and the patient should report any bleeding (position or time) to the treating doctor.

thrombocytopenic thrombocytopenia (TTP)

Blood thrombosis is reported that it is very rare after using clopidogel, sometimes after a short time of medication. A decrease in thrombocytopenia and microchemical disease is related to or neurological results, renal or fever impairment. TTP status is likely to be fatal requiring quick treatment, including plasma extract.

recent fleeting stroke

Due to the lack of facts, it is not recommended to use Clopidogel for the first 7 days after the stroke.

cytochrome C450 2C19 (CYP2C19)

Genetic pharmacology: Based on research data, patients reduce genetic CYP2C19 functions with lower system exposure to clopidogel active metabolites and reduce platelet resistance effect and generally show that the rate of cardiovascular events is higher after heart infarction than patients with normal CYP2C19 functions.

Because Clopidogel is converted into active ingredient with partial activity of CYP2C19 enzyme measurement, the use of enzyme inhibitors will lead to a reduction in the concentration of metabolic metabolites of clopidogcl. The clinical correspondence of this interaction is uncertain. The use of CYP2C19 inhibitors should be limited.

kidney failure

Experience in clopidogel in patients with renal failure is limited. Therefore should be cautious when using clopidogel in these patients.

liver failure

Clopidogel treatment experience in patients with hepatic impairment is at risk of organs. Therefore should be cautious when using clopidogel in these patients.

used for pregnant or lactating women

Because there is no clinical evidence on the exposure to clopidogel during pregnancy, it is not recommended to use clopidogel during pregnancy.

Animal studies are not directly and indirectly affecting the harmful effects on pregnancy, embryo development, childbirth or fetal development.

There is no evidence whether Clopidogel is excreted through breast milk or not.

Animal research shows clopidogel excretion through breast milk. To prevent, do not breastfeed during the time of using Clopidogel.

The effect of the drug on driving and operating machinery

Clopidogel does not affect or negligible on the ability to drive and operate machinery.

Interactive drug

Oral anti -oral drugs do not recommend the use of clopidogel with oral anti -oral drugs due to increasing bleeding level.

Glycoprotein II/Illa inhibitors: Be cautious when used with clopidogel with glycoprotein jib/ila inhibitors.

acetylsalicylate (ASA): ASA does not add inhibition of platelet aggregation effects due to ADP through intermediaries Clopidoge. However, the use of 500mg ASA 2 times a day in a day does not significantly increase the extension of the bleeding time due to clopidogel. Pharmaceutical interaction can occur between clopidogel and Asa, leading to an increase in the risk of bleeding. Therefore, be careful when using these drugs. However, Clopidogel and ASA can use cream for up to 1 year.

Heparin: A clinical study conducted in healthy people, clopidogel does not act on the dose of heparin or changing the effect of heparin on blood clotting. The use of heparin does not affect the inhibition of platelet gathering of clopidogel. A pharmaceutical interaction may occur between clopidogel and Asa, leading to an increased risk of bleeding. Therefore, be careful when using these drugs.

Blood soluble drugs: Safety when used with clopidogel, fibrin or typical non -fibrin hemolysis drugs and heparins are evaluated in patients with acute myocardial infarction. The frequency of serious clinical bleeding is similar to the frequency of observation when used with medications that cause thrombosis and heparin with ASA.

Nasaid: A clinical study conducted in healthy people, the use of clopidogel with naproxen causing hemorrhage to hemorr the gastrointestinal bleeding. However, due to the lack of interactive studies with other NSAIDs, it is still unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. Therefore, be careful when used with NSAIDs including Cox-2 and Clopidogel inhibitors.

Other accompanying treatment: Because Clopidogel is converted into active ingredients partially due to CYP2C19 enzymes, the use of active inhibitors of this enzyme will lead to a decrease in the concentration of metabolic metabolites of clopidogel. The clinical correspondence of this interaction is uncertain. The use of CYP2C19 inhibitors should be limited.

CYP2C19 inhibitors include omeprazole and Esomeprazole, Luvoxamine, Fluoxetine, Moclobemide, Voriconazole, Fluconazole, Ticlopidine, Ciprofloxacin, Cimetidine, Carbamazepine, Oxcarbazepine and Cloramphenicol.

The inconsistent data on clinical meanings of this dynamic interaction in the form of a large cardiovascular event has been reported from both observation and clinical research.

The use of omeprazole and Esomeprazole should be limited warning. There is no conclusion data on Clopidoge's pharmacokinetic interaction and other PPIs that do not have evidence of other drugs that reduce gastric acid such as H2 blockers (except Cimetidine la 2 1 inhibit CYP2C19) or acid antacids interact with the anti -platelet impact of clopidogel.

Other drugs:

Some clinical studies have been conducted with clopidogel and other drugs to consider the ability to interact with pharmacological and pharmacological. Not observing a significant clinical pharmaceutical interaction when used with clopidogel with Atenolol, Nifedipine or even 2.
further, Clopidogel's pharmacological activity is not significantly affected by the use of phenobarbital or estrogen.

Data from studies on human liver mucous mucous mucous mucous mucous mucous mucous microscopic shows that clopidogel's carboxylic acid metabolites can inhibit the activity of Cytochrome P450 2C19. This is likely to lead to an increase in plasma concentrations of drugs such as phenytoin and tolbutamide and NSAIDs due to metabolic cytochrome 450.

Data from Caprie research shows that Phenytoin and Tolbutamide can be used safely with Clopidogel.

Except for the above special drug interaction information, interactive studies with clopidogel and some drugs in general are used in patients with arterial thrombosis. However, patients participating in clinical studies with clopidogel receive differential medications such as diuretics, beta blockers, calcium channel blockers, blood cholesterol medications, rimsions, diabetes treatments (including insulin), anti -epileptic drugs and GPIIB/Illa drugs will not have serious drug interactions.